Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Salbutamol has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.
Phoenix Children's Hospital, Phoenix, Arizona, United States
Aeroallergy Research Laboratories of Savannah, Inc., Savannah, Georgia, United States
Rush Presbyterian - St. Luke's Medical Center Rush University, Chicago, Illinois, United States
Research Across America, Dallas, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.